Physiologic vs Chronologic Age

Slides:

Advertisements

Similar presentations

Maintenance therapy for NSCLC

Advertisements

James R. Rigas Comprehensive Thoracic Oncology Program

Treatment in Advanced Non-Small Cell Lung Cancer.

Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.

Using Non-targeted Therapies in Targeted Lung Cancer Populations Nathan Pennell, M.D., Ph.D. September 6, 2014.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Palliative Chemotherapy Dr. Oscar S. Breathnach Consultant Medical Oncologist Palliative Care Multidisciplinary Study Day Beaumont Hospital Sept. 19 th,

First-Line TKI Use in EGFR Mutation-Positive NSCLC

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

Treatment of advanced NSCLC:

Appropriate e sostenibili Alberto Sobrero IRCCS San Martino IST Genova Alberto Sobrero IRCCS San Martino IST Genova.

A novel 3D human tissue culture model

Overall survival in NSCLC

Sumitra Thongprasert, MD

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Contents Introduction Defining “clinically meaningful improvement”

Volume 18, Issue 6, Pages (September 2015)

Recent Advances in NSCLC Treatment

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

CHEMO-IMMUNO-TARGET THERAPIES

Continuous benefit counts

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Continuous benefit counts

SQUIRE: Improved Survival With Necitumumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin as First-line Treatment in Patients With Squamous NSCLC Slideset.

Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.

بنام خداوند جان و خرد.

Caris Molecular Intelligence®

Patient Case 1 Patient Case 1: PET/CT Scan.

Lancet Oncol 2016;17(11): Updated Results from KEYNOTE-021 Cohort G: A Randomized, Phase 2 Study of Pemetrexed and Carboplatin (PC) with or without.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors Alexa B. Schrock,

Advanced NSCLC Without Actionable Mutations

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Robert Klein, MS, Catherine.

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

More Than Meets the Eye.

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Oncologia Polmonare – AOU S. Luigi Gonzaga, Orbassano (To)

Putting Evidence Into Practice: Highlights From Toronto

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

MX39795 Study Design Category 1 R 3:1 Category 2 Inclusion criteria

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Educational Objectives

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

Optimizing Outcomes in Patients With NSCLC and Liver Metastases

Third-Generation EGFR TKIs

Physiologic vs Chronologic Age

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Lung Cancer Basic Overview Patient Forum: 2019

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Physiologic vs Chronologic Age

Learning Objectives

Clinical Scenario

Subgroup Analysis Cisplatin + Pemetrexed vs Cisplatin + Gemcitabine in Non-Squamous NSCLC

Pemetrexed Maintenance in Older Patients With Non-Squamous NSCLC

Frontline nab-Paclitaxel for Advanced NSCLC in Older Patients

Subgroup Analysis Frontline Bevacizumab in Older Patients With Non-Squamous NSCLC

SQUIRE Subgroup Analysis of Gemcitabine/Cisplatin ± Necitumumab

Erlotinib in Older Patients With NSCLC

Gefitinib in Older Patients With EGFR-Mutated NSCLC

Retrospective Analysis of First-Line Gefitinib in Patients ≥ 70 years with EGFR-Mutated NSCLC

LUX-Lung 3 Afatinib vs Cisplatin + Pemetrexed in Metastatic NSCLC

PROFILE 1014 Crizotinib vs Chemotherapy in ALK-Positive NSCLC

Conclusions and Final Thoughts

Abbreviations